Can antenatal dexamethasone prevent mortality and morbidity among late preterm newborns?
India: The largest efficacy trial of antenatal corticosteroids found no substantive changes in the risk estimates for neonatal death, perinatal death, or respiratory distress syndrome, of women receiving antenatal corticosteroids at 34 weeks gestation or greater in a low-resource country setting. The article was published in the Lancet journal eClinicalMedicine.
Globally, 11% of live births babies are born preterm(32 to <37 weeks gestation). Compared to babies born at term, preterm babies have higher rates of respiratory, infectious, and neurological morbidities; elevated risks of adverse health outcomes persisting into childhood and later life. Babies born in the late preterm period (34 to <37 weeks) experience a significantly higher rate of morbidity and mortality than those born at term. (WHO) recommended antenatal corticosteroids (ACS) used for pregnant women at risk of preterm birth from 24 to 34 weeks gestation, but is a lack of evidence of the benefit of ACS beyond 34 weeks. The WHO guideline panel acknowledged that further efficacy trials in low-resource countries on ACS use in both early and late preterm populations were a high research priority. There is currently insufficient evidence on the safety and efficacy of antenatal corticosteroids in preventing mortality and severe morbidity amongst late preterm newborns in low-resource countries.
The results of the WHO ACTION-I(Antenatal CorticosTeroids for Improving Outcomes in preterm Newborn) trial on the efficacy of dexamethasone in the early preterm period have been reported previously. In this article, the authors describe the findings of the WHO ACTION-II trial, which aimed to assess the safety and efficacy of dexamethasone when given to women at risk of late preterm birth, in hospitals in low-resource countries.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.